Ayyildiz, OTiftik, NBolaman, ZMüftüoglu, E2024-04-242024-04-24200088-323-0211-Xhttps://hdl.handle.net/11468/2167812th Mediterranean Congress of Chemotherapy -- NOV 11-14, 2000 -- MARRAKECH, MOROCCOTen patients with B-cell chronic lymphocytic leukemia (CLL), aged 55-72 years, 9 male and 1 female, were treated with fludarabine. Fludarabine is the most active agent for treatment of CLL. All patients were previously treated with alkylating agent-based regimen. Fludarabine was administered for 5 consecutive days 25 mg/m(2)/d and repeated 4-weekly. The response rate was 40% with 1 complete response and 3 partial responses. However, four patients achieved stable disease and 2 progressed. The median survival for responders was 18 months and for non-responders 8 months. Our patients tolerated the fludarabine treatment extremely well. Myelosupression was seen in eight patients. In a total of 37 treatment courses 5 febrile episodes were registered in 4 patients and successfully treated with empirical antibiotic regimen. In conclusion, fludarabine is effective in CLL patients refractory to first-line chemotherapy.eninfo:eu-repo/semantics/closedAccess[No Keyword]Conference Object117121WOS:000172402200018N/A